Mereo Other Cashflows From Financing Activities from 2010 to 2024

MREO Stock  USD 3.73  0.04  1.06%   
Mereo BioPharma Other Cashflows From Financing Activities yearly trend continues to be very stable with very little volatility. Other Cashflows From Financing Activities is likely to drop to about -466.2 K. During the period from 2010 to 2024, Mereo BioPharma Other Cashflows From Financing Activities quarterly data regression pattern had sample variance of 64.1 T and median of (868,000). View All Fundamentals
 
Other Cashflows From Financing Activities  
First Reported
2017-06-30
Previous Quarter
46.8 M
Current Value
-594 K
Quarterly Volatility
13.8 M
 
Covid
Check Mereo BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mereo BioPharma's main balance sheet or income statement drivers, such as Interest Income of 2.2 M, Discontinued Operations of 0.0 or Interest Expense of 2.9 M, as well as many indicators such as Price To Sales Ratio of 135, Dividend Yield of 0.0 or PTB Ratio of 31.65. Mereo financial statements analysis is a perfect complement when working with Mereo BioPharma Valuation or Volatility modules.
  
Check out the analysis of Mereo BioPharma Correlation against competitors.

Latest Mereo BioPharma's Other Cashflows From Financing Activities Growth Pattern

Below is the plot of the Other Cashflows From Financing Activities of Mereo BioPharma Group over the last few years. It is Mereo BioPharma's Other Cashflows From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mereo BioPharma's overall financial position and show how it may be relating to other accounts over time.
Other Cashflows From Financing Activities10 Years Trend
Pretty Stable
   Other Cashflows From Financing Activities   
       Timeline  

Mereo Other Cashflows From Financing Activities Regression Statistics

Arithmetic Mean(980,083)
Geometric Mean1,150,631
Coefficient Of Variation(817.12)
Mean Deviation3,326,662
Median(868,000)
Standard Deviation8,008,502
Sample Variance64.1T
Range42.1M
R-Value(0.12)
Mean Square Error68.1T
R-Squared0.01
Significance0.67
Slope(211,842)
Total Sum of Squares897.9T

Mereo Other Cashflows From Financing Activities History

2024-466.2 K
2023-444 K
2022350 K
2021-253.7 K
2020-23.4 M
2019-2.5 M
2018-2 M

About Mereo BioPharma Financial Statements

Mereo BioPharma investors utilize fundamental indicators, such as Other Cashflows From Financing Activities, to predict how Mereo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Cashflows From Financing Activities-444 K-466.2 K

Pair Trading with Mereo BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mereo Stock

  0.7EQ EquilliumPairCorr
  0.76ME 23Andme HoldingPairCorr
  0.85VALN Valneva SE ADRPairCorr

Moving against Mereo Stock

  0.82VCEL Vericel Corp OrdPairCorr
  0.76VCYT VeracytePairCorr
  0.7DRTS Alpha Tau MedicalPairCorr
  0.57DMAC DiaMedica TherapeuticsPairCorr
  0.56SABSW SAB BiotherapeuticsPairCorr
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:
Check out the analysis of Mereo BioPharma Correlation against competitors.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.25)
Revenue Per Share
0.007
Return On Assets
(0.24)
Return On Equity
(0.48)
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.